Sanket Shah is a distinguished biopharmaceutical executive with extensive global market access and expertise in health outcomes research (HEOR). As Director of Global Value and HEOR at Jazz Pharmaceuticals, Sanket leads value demonstration strategies for a $2.8 billion neuroscience portfolio, ensuring therapeutic innovations successfully reach patients while meeting critical payer requirements.

Throughout his career, Sanket has demonstrated an exceptional ability to bridge clinical expertise as a physician with sophisticated health economics leadership. At Novo Nordisk, he built and led the company’s first Rare Disease HEOR function, growing the team from inception while protecting $500 million in revenue. His innovative approach to reimbursement frameworks has consistently enabled commercial success across both pipeline and marketed products.

Sanket brings a unique combination of medical knowledge and business acumen to complex market access challenges. He has established himself as a trusted strategic advisor in clinical development optimization, having shaped trial designs through careful integration of payer requirements across US and EU markets. His systematic approach to value demonstration has proven particularly valuable in rare diseases and specialty therapeutics, where he has created patient-centric frameworks that align clinical development with payer requirements and regulatory expectations.

Before his current role, Sanket served as Head of US HEOR for Rare Disease at Novo Nordisk, where he led market access and value strategy for a 14-product portfolio exceeding $1 billion in revenue. His early career included valuable experience at Stratevi, where he advised early-stage biotechnology companies on global evidence-generation strategies.

Additionally, Sanket is an avid angel investor and scientific advisor to technology forward healthcare and life science startups looking to scale and improve complex healthcare problems with digital solutions. He partners with them on data strategy, scientific leadership, and value proposition development with a biopharma focus.

Sanket holds a Ph.D. in Health Economics and Outcomes with a minor in Business from the University of Texas at Austin and an MBBS from Maharashtra University of Health Sciences. He combines this strong academic foundation with practical business insights gained through certifications from the Wharton Business School in Marketing, Negotiation, and Influence.